Synageva BioPharma Inactive 10-Q2008 Q1 Quarterly report

Filed: 12 May 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accessible, aggregate, alleged, alleging, Antigenic, ascending, assumption, auction, Bank, blended, Blood, brought, case, ceased, Center, classified, collateralized, collectively, Columbia, comment, complaint, Composition, consent, creating, declared, deteriorate, directly, disposal, dividend, dollar, entitled, env, expedient, expertise, favorable, fluctuate, formal, forward, framework, gag, Gain, hierarchy, identical, indirectly, input, introduction, issuance, lawsuit, liquidation, litigation, lowest, move, NAV, objective, observable, open, optimize, oral, orderly, Polypeptide, preliminary, proposed, resolve, SAD, satisfactory, seek, short, single, suit, surpassed, suspended, Task, transparency, trend, Unadjusted, understanding, unobservable, unrestricted, York

Removed: achieve, acquisition, adequacy, adverse, advisory, age, amortizing, anticipating, arise, arising, Array, attract, back, Biopharma, biotechnology, Bolognesi, bonczek, call, capacity, certainty, commercialized, comparable, consisted, continuation, convertible, correctly, credited, CRL, cut, Dani, Delaware, Department, deploy, developmental, difficulty, direction, disposition, eligibility, eligible, employment, establishment, exceed, explanation, extremely, fail, finance, Franchise, funding, grant, guaranteed, hand, Hickey, highly, hill, incorporated, incurring, industry, infection, institution, internally, issuing, leadership, legal, magnitude, meeting, merger, model, modified, month, Neokimia, netted, nonrefundable, notified, obtained, offering, opportunity, ordinary, owe, participating, pipeline, potential, preferred, premium, President, principally, prohibit, prospective, protesting, purpose, pursue, qualified, raw, receive, recognize, relinquish, restrict, restrictive, retain, retirement, robert, scientific, scope, settled, shown, speculate, spouse, state, stop, subsequently, supported, technological, termination, test, therapeutic, traded, transaction, ultimate, ultimately, unconsolidated, unexercised, unwilling, utilize, viability, volatile, voluntary, warrant, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Synageva BioPharma similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Trimeris, Inc. (the “Company”) for the quarterly period ended March 31, 2008 as filed with Securities and Exchange Commission on the date hereof (the “Report”), I, Andrew L. Graham, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ ANDREW L. GRAHAM

Andrew L. Graham

Chief Financial Officer

and Secretary (Principal Accounting Officer)

May 12, 2008

The foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the Report or as a separate disclosure document.

A signed original of this written statement required by § 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.